Physician profile
Arvind Bakhru
NPI 1477689511
$7,453.60
in general payments reported to CMS, 2019-2025
21 companies · $291 in 2025
The $291 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,747 · 2020: $1,414 · 2021: $346 · 2022: $369 · 2023: $2,148 · 2024: $140 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,950 · Food and Beverage: $528 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,950.00 |
| Food and Beverage | $528.15 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,255.81 | 2020-2025 | Jemperli, Zejula |
| Tesaro, INC. | $2,500.00 | 2019 | |
| Intuitive Surgical, INC. | $362.57 | 2020-2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $321.07 | 2019-2025 | Lynparza |
| Baxter Healthcare | $286.20 | 2019-2022 | |
| Genmab U.S., INC. | $147.33 | 2021-2024 | Tivdak |
| On Target Laboratories, INC | $125.20 | 2025 | Cytalux |
| Myriad Genetic Laboratories, INC. | $109.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $74.02 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $70.52 | 2019-2024 | Keytruda |
| Genzyme Corporation | $31.42 | 2025 | |
| Amgen INC. | $30.27 | 2019 | |
| Eisai INC. | $23.07 | 2023 | |
| Daiichi Sankyo INC. | $21.05 | 2019 | |
| Abbvie INC. | $15.95 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Accelerator Applications | $15.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.89 | 2019 | |
| Pfizer INC. | $13.45 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $13.13 | 2020 | |
| Jazz Pharmaceuticals INC. | $12.23 | 2020 | |
| Foundation Medicine, INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Bakhru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.